<p>Invivyd（纳斯达克股票代码：IVVD - 获取免费报告）于周四发布了季度财报。该公司报告本季度每股收益为（$0.13），低于市场共识预期的（$0.08）$0.05，FiscalAI 报道。该季度的收入为 1374 万美元，而分析师的预期为 1804 万美元。Invivyd 的净利润率为-98.25%，股本回报率为-48.65%。</p>
<p>以下是 Invivyd 电话会议的主要要点：</p>
<ul>
<li>Invivyd 表示其 <strong>DECLARATION</strong> 关键研究对于 VYD2311 进展迅速，扩大后的队列填充速度超出预期，招募现已恢复全速进行，保持项目进度。</li>
<li>公司强调 IDMC 建议将 <strong>剂后监测</strong> 从 2 小时减少到 30 分钟，经过对未盲化安全数据的审查，管理层认为这是耐受性良好的积极信号。</li>
<li>Invivyd 表示其药物继续对当前 SARS-CoV-2 变种表现出 <strong>强大的中和能力</strong>，包括对 Omicron BA.3.2 的正式确认，支持其产品在不断变化的病毒环境中仍然具有相关性。</li>
<li>在商业方面，<strong>PEMGARDA 的收入同比增长 22%</strong>，管理层表示尽管面临正常的季节性阻力和疫苗使用的整体下降，增长依然稳健。</li>
<li>公司在季度末结束时拥有 <strong>强劲的现金状况</strong>，在 4 月进行额外的 ATM 融资后，预计随着 VYD2311 试验在未来几个季度的结束，研发支出将恢复正常。</li>
</ul>
<h2>Invivyd 股价下跌 21.1%</h2>
<p>周四中午，纳斯达克 IVVD 的股价下跌 0.31 美元，达到 1.16 美元。该公司交易了 11,515,578 股，交易量高于其平均交易量 1,634,102 股。该股票的市值为 3.2805 亿美元，市盈率为-3.63，贝塔值为 0.71。Invivyd 的 1 年最低价为 0.48 美元，1 年最高价为 3.07 美元。该股票的 50 日简单移动平均为 1.53 美元，200 日简单移动平均为 1.91 美元。</p>
<h2>内部交易活动</h2>
<p>在其他 Invivyd 新闻中，内部人士 Timothy Edward Lee 于 2 月 18 日星期三出售了 20,964 股该股票。股票以平均价格 1.58 美元出售，总交易额为 33,123.12 美元。交易完成后，该内部人士直接持有 117,717 股公司股票，价值约 185,992.86 美元。这笔交易代表其持股减少了 15.12%。该交易已在与证券交易委员会的法律文件中披露，可通过 SEC 网站访问。此外，首席财务官 William E. Duke 于 2 月 18 日星期三出售了 20,964 股公司的股票。股票以平均价格 1.58 美元出售，总价值为 33,123.12 美元。交易完成后，首席财务官直接持有 107,717 股公司股票，价值约 170,192.86 美元。这笔交易代表其持股减少了 16.29%。该销售的披露可在 SEC 文件中找到。内部人士在上个季度出售了 227,172 股公司股票，价值 354,534 美元。12.25% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近增加或减少了对公司的持股。Janus Henderson Group PLC 在第四季度将其在 Invivyd 的股份增加了 28.2%。Janus Henderson Group PLC 现在拥有 32,543,142 股公司股票，价值 80,870,000 美元，在上个季度又购买了 7,160,065 股。RA Capital Management L.P.在第三季度获得了 Invivyd 的新头寸，价值 18,831,000 美元。ADAR1 Capital Management LLC 在第三季度购买了约 8,108,000 美元的 Invivyd 新股份。Vanguard Group Inc.在第三季度将其在 Invivyd 的持股增加了 46.7%。Vanguard Group Inc.现在拥有 5,762,894 股公司股票，价值 6,339,000 美元，在上个季度又购买了 1,834,970 股。最后，State Street Corp 在第四季度将其在 Invivyd 的持股增加了 1,636.7%。State Street Corp 现在拥有 5,637,593 股公司股票，价值 13,925,000 美元，在上个季度又购买了 5,312,986 股。70.36% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票研究分析师最近对该股票发表了看法。BTIG Research 在 2 月 26 日的报告中重申了 “买入” 评级，并对 Invivyd 的股票设定了 10.00 美元的目标价。Weiss Ratings 在 4 月 29 日的研究报告中重申了对 Invivyd 的 “卖出（d-）” 评级。最后，HC Wainwright 在周四的研究报告中重申了对 Invivyd 的 “买入” 评级。三位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “持有”，平均目标价为 8.00 美元。</p>
<p><strong>查看我们最新的 IVVD 股票分析</strong></p>
<h2>Invivyd 公司简介</h2>
<p>（获取免费报告）</p>
<p>Invivyd, Inc 是一家商业阶段的生物制药公司，专注于在美国发现、开发和商业化针对传染病的抗体解决方案。该公司开发了 INVYMAB，一个将病毒监测和预测建模与先进抗体工程相结合的平台。其产品线包括 PEMGRADA（pemivibart）注射剂，一种用于预防成人和青少年 COVID-19 的半衰期延长的实验性单克隆抗体（mAb）；VYD2311，一种正在进行预临床研究的 mAb 候选药物，用于预防或治疗 COVID-19；以及正在进行第三阶段临床试验的 adintrvimab，用于预防或治疗 COVID-19。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而非 Invivyd</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：目前显然更具价值的选择是前者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVZWRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVZWRA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Invivyd 吗？</h2>
<p>在考虑 Invivyd 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Invivyd 并不在名单上。</p>
<p>虽然 Invivyd 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IVVD

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - Vanguard

<p>Invivyd (NASDAQ:IVVD) 报告的季度每股收益为（$0.13），低于预期（$0.05），收入为 1374 万美元，低于预期的 1804 万美元。该公司的股本回报率为负 48.65%，净利润率为 98.25%。尽管面临挑战，Invivyd 的 VYD2311 研究进展顺利，PEMGARDA 的收入同比增长 22%。股价下跌 21.1%，至$1.16，且有显著的内部人士抛售。机构投资者增加了持股比例，70.36% 的股份由对冲基金持有</p>

<p>Invivyd (NASDAQ:IVVD - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.05), FiscalAI reports. The business had revenue of $13.74 million during the quarter, compared to analysts' expectations of $18.04 million. Invivyd had a negative net margin of 98.25% and a negative return on equity of 48.65%.</p>
<div class="lb-trans"><p>Invivyd（纳斯达克股票代码：IVVD - 获取免费报告）于周四发布了季度财报。该公司报告本季度每股收益为（$0.13），低于市场共识预期的（$0.08）$0.05，FiscalAI 报道。该季度的收入为 1374 万美元，而分析师的预期为 1804 万美元。Invivyd 的净利润率为-98.25%，股本回报率为-48.65%。</p>
</div><p>Here are the key takeaways from Invivyd's conference call:</p>
<div class="lb-trans"><p>以下是 Invivyd 电话会议的主要要点：</p>
</div><ul>
<li>Invivyd said its <strong>DECLARATION</strong> pivotal study for VYD2311 is progressing quickly, with the upsized cohort filling faster than expected and recruitment now resumed at full speed, keeping the program on track.</li>
<li>The company highlighted an IDMC recommendation to <strong>reduce post-dose monitoring</strong> from 2 hours to 30 minutes after reviewing unblinded safety data, which management views as an encouraging sign for tolerability.</li>
<li>Invivyd said its medicines continue to show <strong>strong neutralization against current SARS-CoV-2 variants</strong>, including formal confirmation against Omicron BA.3.2, supporting its view that the product remains relevant to the evolving virus landscape.</li>
<li>Commercially, <strong>PEMGARDA revenue grew 22% year over year</strong> in the first quarter, and management said growth remains solid despite normal seasonal headwinds and broader declines in vaccine utilization.</li>
<li>The company ended the quarter with a <strong>strong cash position</strong> after additional April ATM financing, and expects R&amp;D spending to normalize as the VYD2311 trial winds down over coming quarters.</li>
</ul>
<div class="lb-trans"><ul>
<li>Invivyd 表示其 <strong>DECLARATION</strong> 关键研究对于 VYD2311 进展迅速，扩大后的队列填充速度超出预期，招募现已恢复全速进行，保持项目进度。</li>
<li>公司强调 IDMC 建议将 <strong>剂后监测</strong> 从 2 小时减少到 30 分钟，经过对未盲化安全数据的审查，管理层认为这是耐受性良好的积极信号。</li>
<li>Invivyd 表示其药物继续对当前 SARS-CoV-2 变种表现出 <strong>强大的中和能力</strong>，包括对 Omicron BA.3.2 的正式确认，支持其产品在不断变化的病毒环境中仍然具有相关性。</li>
<li>在商业方面，<strong>PEMGARDA 的收入同比增长 22%</strong>，管理层表示尽管面临正常的季节性阻力和疫苗使用的整体下降，增长依然稳健。</li>
<li>公司在季度末结束时拥有 <strong>强劲的现金状况</strong>，在 4 月进行额外的 ATM 融资后，预计随着 VYD2311 试验在未来几个季度的结束，研发支出将恢复正常。</li>
</ul>
</div><h2>Invivyd Trading Down 21.1%</h2>
<div class="lb-trans"><h2>Invivyd 股价下跌 21.1%</h2>
</div><p>Shares of NASDAQ IVVD traded down $0.31 during midday trading on Thursday, reaching $1.16. 11,515,578 shares of the company were exchanged, compared to its average volume of 1,634,102. The stock has a market cap of $328.05 million, a P/E ratio of -3.63 and a beta of 0.71. Invivyd has a 1 year low of $0.48 and a 1 year high of $3.07. The stock has a fifty day simple moving average of $1.53 and a 200 day simple moving average of $1.91.</p>
<div class="lb-trans"><p>周四中午，纳斯达克 IVVD 的股价下跌 0.31 美元，达到 1.16 美元。该公司交易了 11,515,578 股，交易量高于其平均交易量 1,634,102 股。该股票的市值为 3.2805 亿美元，市盈率为-3.63，贝塔值为 0.71。Invivyd 的 1 年最低价为 0.48 美元，1 年最高价为 3.07 美元。该股票的 50 日简单移动平均为 1.53 美元，200 日简单移动平均为 1.91 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other Invivyd news, insider Timothy Edward Lee sold 20,964 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the sale, the insider directly owned 117,717 shares of the company's stock, valued at approximately $185,992.86. This trade represents a 15.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CFO William E. Duke sold 20,964 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $33,123.12. Following the completion of the transaction, the chief financial officer directly owned 107,717 shares in the company, valued at approximately $170,192.86. The trade was a 16.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 227,172 shares of company stock worth $354,534 over the last quarter. 12.25% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Invivyd 新闻中，内部人士 Timothy Edward Lee 于 2 月 18 日星期三出售了 20,964 股该股票。股票以平均价格 1.58 美元出售，总交易额为 33,123.12 美元。交易完成后，该内部人士直接持有 117,717 股公司股票，价值约 185,992.86 美元。这笔交易代表其持股减少了 15.12%。该交易已在与证券交易委员会的法律文件中披露，可通过 SEC 网站访问。此外，首席财务官 William E. Duke 于 2 月 18 日星期三出售了 20,964 股公司的股票。股票以平均价格 1.58 美元出售，总价值为 33,123.12 美元。交易完成后，首席财务官直接持有 107,717 股公司股票，价值约 170,192.86 美元。这笔交易代表其持股减少了 16.29%。该销售的披露可在 SEC 文件中找到。内部人士在上个季度出售了 227,172 股公司股票，价值 354,534 美元。12.25% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its stake in shares of Invivyd by 28.2% during the 4th quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company's stock worth $80,870,000 after buying an additional 7,160,065 shares in the last quarter. RA Capital Management L.P. acquired a new position in shares of Invivyd during the 3rd quarter worth $18,831,000. ADAR1 Capital Management LLC purchased a new stake in shares of Invivyd in the third quarter valued at about $8,108,000. Vanguard Group Inc. lifted its holdings in shares of Invivyd by 46.7% in the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company's stock valued at $6,339,000 after purchasing an additional 1,834,970 shares in the last quarter. Finally, State Street Corp grew its position in shares of Invivyd by 1,636.7% in the fourth quarter. State Street Corp now owns 5,637,593 shares of the company's stock valued at $13,925,000 after purchasing an additional 5,312,986 shares during the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对公司的持股。Janus Henderson Group PLC 在第四季度将其在 Invivyd 的股份增加了 28.2%。Janus Henderson Group PLC 现在拥有 32,543,142 股公司股票，价值 80,870,000 美元，在上个季度又购买了 7,160,065 股。RA Capital Management L.P.在第三季度获得了 Invivyd 的新头寸，价值 18,831,000 美元。ADAR1 Capital Management LLC 在第三季度购买了约 8,108,000 美元的 Invivyd 新股份。Vanguard Group Inc.在第三季度将其在 Invivyd 的持股增加了 46.7%。Vanguard Group Inc.现在拥有 5,762,894 股公司股票，价值 6,339,000 美元，在上个季度又购买了 1,834,970 股。最后，State Street Corp 在第四季度将其在 Invivyd 的持股增加了 1,636.7%。State Street Corp 现在拥有 5,637,593 股公司股票，价值 13,925,000 美元，在上个季度又购买了 5,312,986 股。70.36% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities research analysts have recently weighed in on the stock. BTIG Research restated a &#34;buy&#34; rating and issued a $10.00 price objective on shares of Invivyd in a report on Thursday, February 26th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Invivyd in a research note on Wednesday, April 29th. Finally, HC Wainwright restated a &#34;buy&#34; rating on shares of Invivyd in a research note on Thursday. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and an average price target of $8.00.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该股票发表了看法。BTIG Research 在 2 月 26 日的报告中重申了 “买入” 评级，并对 Invivyd 的股票设定了 10.00 美元的目标价。Weiss Ratings 在 4 月 29 日的研究报告中重申了对 Invivyd 的 “卖出（d-）” 评级。最后，HC Wainwright 在周四的研究报告中重申了对 Invivyd 的 “买入” 评级。三位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “持有”，平均目标价为 8.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on IVVD</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 IVVD 股票分析</strong></p>
</div><h2>Invivyd Company Profile</h2>
<div class="lb-trans"><h2>Invivyd 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.</p>
<div class="lb-trans"><p>Invivyd, Inc 是一家商业阶段的生物制药公司，专注于在美国发现、开发和商业化针对传染病的抗体解决方案。该公司开发了 INVYMAB，一个将病毒监测和预测建模与先进抗体工程相结合的平台。其产品线包括 PEMGRADA（pemivibart）注射剂，一种用于预防成人和青少年 COVID-19 的半衰期延长的实验性单克隆抗体（mAb）；VYD2311，一种正在进行预临床研究的 mAb 候选药物，用于预防或治疗 COVID-19；以及正在进行第三阶段临床试验的 adintrvimab，用于预防或治疗 COVID-19。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Invivyd</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Invivyd</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：目前显然更具价值的选择是前者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVZWRA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IVVD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Invivyd Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Invivyd 吗？</h2>
</div><p>Before you consider Invivyd, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Invivyd 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Invivyd 并不在名单上。</p>
</div><p>While Invivyd currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Invivyd 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Invivyd（NASDAQ 代码：IVVD）公布了财报结果